Sexual Wellness & Defense

PT-141 · Bremelanotide

Centrally acting, on-demand support for desire and arousal.

Centrally-Acting Support
Desire & Arousal Pathway
Provider-Directed Dosing

Starting at $189/month

1 mo · 5 Milliliter$189
3 mo · 15 Milliliter$567
6 mo · 30 Milliliter$1,134
12 mo · 60 Milliliter$2,268

Talk to a Provider

Prescription only where clinically appropriate, following provider evaluation.

PT-141 · Bremelanotide — product photograph

Form & cadence

Subcutaneous injection · On-demand

Investment

Personalized plans are shared after provider review. Pricing varies by therapy and treatment plan, and medication cost is disclosed transparently before you commit.

Overview

A provider-prescribed centrally acting melanocortin receptor agonist that may help support sexual desire and arousal in eligible adults, when a licensed provider determines treatment is appropriate.

PT-141 (Bremelanotide) is a centrally acting melanocortin receptor agonist used to help support sexual desire and arousal. It is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women and is also used off-label in men with low libido or erectile dysfunction, particularly where central causes are suspected. Unlike traditional PDE5 medications, PT-141 works through the central nervous system rather than by acting on blood flow.

How it works

The mechanism

PT-141 activates melanocortin receptors (MC3R and MC4R) in the hypothalamus, supporting sexual desire and drive through central nervous system pathways. It does not depend on nitric oxide pathways or vascular mechanisms.

Candidacy

Who it's for

—Adults with concerns related to sexual desire or arousal that are not primarily vascular
—Patients seeking an option outside the PDE5 inhibitor class
—Adults evaluated by a licensed provider to determine eligibility

Benefits it may support

What good care can do.

Individual response varies. Our providers define realistic outcomes with you before any protocol begins, and refine the plan as your body responds.

—May support intimate function, confidence and quality of life
—Discreet, provider-managed prescriptions with continuity of care
—Reviewed against cardiovascular, hormonal and medication history
—Designed to help address the presenting concern and the upstream picture together

What to expect

A calibrated timeline.

After your assessment, our provider reviews your history and, where indicated, orders baseline labs. If pt-141 · bremelanotide is clinically appropriate, your personalized protocol is prescribed and shipped discreetly. From there, care is continuous — with scheduled check-ins, adjustment where needed and ongoing medical oversight throughout your plan.

Onset

Administered by subcutaneous injection approximately 45–60 minutes before sexual activity; onset is typically 45–60 minutes.

Duration

Effect typically lasts approximately 6–12 hours. Follow your provider's directions on dosing frequency.

Safety & side effects

Responsibly prescribed.

Common side effects may include nausea (often transient), flushing or warmth, headache and injection-site reactions. Less common effects that should be monitored include temporary elevation in blood pressure, fatigue or yawning, dizziness, and rarely darkening of gums or skin with prolonged use. Not recommended for adults with uncontrolled hypertension or significant cardiovascular disease. Do not exceed the dosing frequency prescribed by your provider.

This is a summary, not a complete list of considerations. Your provider will review the full risk-benefit picture, personal and family history, current medications and contraindications before any protocol is prescribed.

Provider oversight

Care that continues.

Every protocol is prescribed and managed by a US board-certified provider. Dose adjustments, ancillary medications, laboratory cadence and de-escalation decisions are made by your provider, not by a template.

Secure messaging keeps the conversation open between visits. When labs or symptoms suggest a change, we adjust. When a protocol has done its work, we say so.

Questions